nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—SLC6A3—Gilles de la Tourette syndrome	0.543	0.635	CbGaD
Atomoxetine—HTR2A—Gilles de la Tourette syndrome	0.312	0.365	CbGaD
Atomoxetine—SLC6A2—autonomic nervous system—Gilles de la Tourette syndrome	0.00693	0.137	CbGeAlD
Atomoxetine—HTR2A—autonomic nervous system—Gilles de la Tourette syndrome	0.00417	0.0822	CbGeAlD
Atomoxetine—NPY1R—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00413	0.0472	CbGpPWpGaD
Atomoxetine—NPY1R—nervous system—Gilles de la Tourette syndrome	0.00258	0.051	CbGeAlD
Atomoxetine—NPY1R—central nervous system—Gilles de la Tourette syndrome	0.00249	0.0491	CbGeAlD
Atomoxetine—NPY1R—brain—Gilles de la Tourette syndrome	0.00197	0.0389	CbGeAlD
Atomoxetine—HTR6—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	0.00185	0.0211	CbGpPWpGaD
Atomoxetine—HTR1D—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	0.00183	0.021	CbGpPWpGaD
Atomoxetine—HTR6—nervous system—Gilles de la Tourette syndrome	0.00182	0.0359	CbGeAlD
Atomoxetine—HTR1B—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	0.0018	0.0205	CbGpPWpGaD
Atomoxetine—HTR6—central nervous system—Gilles de la Tourette syndrome	0.00175	0.0345	CbGeAlD
Atomoxetine—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A3—Gilles de la Tourette syndrome	0.0017	0.0194	CbGpPWpGaD
Atomoxetine—HTR6—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00152	0.0174	CbGpPWpGaD
Atomoxetine—HTR1D—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00151	0.0173	CbGpPWpGaD
Atomoxetine—HTR1B—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00148	0.0169	CbGpPWpGaD
Atomoxetine—HTR6—brain—Gilles de la Tourette syndrome	0.00139	0.0274	CbGeAlD
Atomoxetine—HTR2C—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	0.00136	0.0156	CbGpPWpGaD
Atomoxetine—HTR1B—midbrain—Gilles de la Tourette syndrome	0.00133	0.0263	CbGeAlD
Atomoxetine—SLC6A3—midbrain—Gilles de la Tourette syndrome	0.00132	0.0261	CbGeAlD
Atomoxetine—SLC6A4—Monoamine Transport—SLC6A3—Gilles de la Tourette syndrome	0.0013	0.0149	CbGpPWpGaD
Atomoxetine—HTR6—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0013	0.0148	CbGpPWpGaD
Atomoxetine—HTR1D—midbrain—Gilles de la Tourette syndrome	0.00129	0.0255	CbGeAlD
Atomoxetine—HTR1D—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00129	0.0147	CbGpPWpGaD
Atomoxetine—HTR2C—midbrain—Gilles de la Tourette syndrome	0.00128	0.0252	CbGeAlD
Atomoxetine—HTR1B—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00126	0.0144	CbGpPWpGaD
Atomoxetine—HTR6—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00126	0.0144	CbGpPWpGaD
Atomoxetine—HTR1D—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00125	0.0143	CbGpPWpGaD
Atomoxetine—HTR1B—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00123	0.014	CbGpPWpGaD
Atomoxetine—SLC6A4—midbrain—Gilles de la Tourette syndrome	0.00121	0.0239	CbGeAlD
Atomoxetine—SLC6A2—Amine compound SLC transporters—SLC6A3—Gilles de la Tourette syndrome	0.00118	0.0135	CbGpPWpGaD
Atomoxetine—HTR6—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00117	0.0134	CbGpPWpGaD
Atomoxetine—HTR1D—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00117	0.0133	CbGpPWpGaD
Atomoxetine—HTR1B—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00114	0.013	CbGpPWpGaD
Atomoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00112	0.0128	CbGpPWpGaD
Atomoxetine—SLC6A2—Monoamine Transport—SLC6A3—Gilles de la Tourette syndrome	0.00112	0.0128	CbGpPWpGaD
Atomoxetine—HTR1B—nervous system—Gilles de la Tourette syndrome	0.0011	0.0216	CbGeAlD
Atomoxetine—HTR6—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00109	0.0125	CbGpPWpGaD
Atomoxetine—SLC6A3—nervous system—Gilles de la Tourette syndrome	0.00109	0.0214	CbGeAlD
Atomoxetine—HTR1D—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00108	0.0124	CbGpPWpGaD
Atomoxetine—HTR1B—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00106	0.0121	CbGpPWpGaD
Atomoxetine—HTR1D—nervous system—Gilles de la Tourette syndrome	0.00106	0.0209	CbGeAlD
Atomoxetine—HTR6—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00106	0.0121	CbGpPWpGaD
Atomoxetine—HTR1B—central nervous system—Gilles de la Tourette syndrome	0.00105	0.0208	CbGeAlD
Atomoxetine—HTR1D—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00105	0.012	CbGpPWpGaD
Atomoxetine—HTR2C—nervous system—Gilles de la Tourette syndrome	0.00105	0.0207	CbGeAlD
Atomoxetine—SLC6A3—central nervous system—Gilles de la Tourette syndrome	0.00105	0.0206	CbGeAlD
Atomoxetine—HTR1B—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00103	0.0118	CbGpPWpGaD
Atomoxetine—HTR1D—central nervous system—Gilles de la Tourette syndrome	0.00102	0.0201	CbGeAlD
Atomoxetine—HTR2C—central nervous system—Gilles de la Tourette syndrome	0.00101	0.02	CbGeAlD
Atomoxetine—SLC6A4—nervous system—Gilles de la Tourette syndrome	0.000996	0.0196	CbGeAlD
Atomoxetine—HTR6—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000987	0.0113	CbGpPWpGaD
Atomoxetine—HTR1D—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00098	0.0112	CbGpPWpGaD
Atomoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.000974	0.0111	CbGpPWpGaD
Atomoxetine—HTR1B—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000959	0.011	CbGpPWpGaD
Atomoxetine—SLC6A4—central nervous system—Gilles de la Tourette syndrome	0.000959	0.0189	CbGeAlD
Atomoxetine—HTR2C—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.000957	0.0109	CbGpPWpGaD
Atomoxetine—HTR2C—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.000929	0.0106	CbGpPWpGaD
Atomoxetine—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HTR2A—Gilles de la Tourette syndrome	0.000904	0.0103	CbGpPWpGaD
Atomoxetine—SLC6A2—nervous system—Gilles de la Tourette syndrome	0.000877	0.0173	CbGeAlD
Atomoxetine—HTR2C—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.000865	0.00989	CbGpPWpGaD
Atomoxetine—SLC6A2—central nervous system—Gilles de la Tourette syndrome	0.000844	0.0167	CbGeAlD
Atomoxetine—HTR1B—brain—Gilles de la Tourette syndrome	0.000837	0.0165	CbGeAlD
Atomoxetine—SLC6A3—brain—Gilles de la Tourette syndrome	0.000831	0.0164	CbGeAlD
Atomoxetine—HTR2A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.000831	0.00949	CbGpPWpGaD
Atomoxetine—HTR6—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000823	0.0094	CbGpPWpGaD
Atomoxetine—HTR1D—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000816	0.00933	CbGpPWpGaD
Atomoxetine—HTR1D—brain—Gilles de la Tourette syndrome	0.000811	0.016	CbGeAlD
Atomoxetine—HTR2A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.000806	0.00921	CbGpPWpGaD
Atomoxetine—HTR2C—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000804	0.00919	CbGpPWpGaD
Atomoxetine—HTR2C—brain—Gilles de la Tourette syndrome	0.000803	0.0158	CbGeAlD
Atomoxetine—HTR1B—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000799	0.00914	CbGpPWpGaD
Atomoxetine—Diphenylpyraline—SLC6A3—Gilles de la Tourette syndrome	0.000781	0.119	CrCbGaD
Atomoxetine—HTR2C—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000781	0.00892	CbGpPWpGaD
Atomoxetine—SLC6A4—brain—Gilles de la Tourette syndrome	0.000761	0.015	CbGeAlD
Atomoxetine—HTR2A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.000751	0.00858	CbGpPWpGaD
Atomoxetine—NPY1R—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.000732	0.00837	CbGpPWpGaD
Atomoxetine—Duloxetine—SLC6A3—Gilles de la Tourette syndrome	0.000729	0.111	CrCbGaD
Atomoxetine—HTR2C—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000727	0.00831	CbGpPWpGaD
Atomoxetine—NPY1R—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.000711	0.00812	CbGpPWpGaD
Atomoxetine—HTR2A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000698	0.00798	CbGpPWpGaD
Atomoxetine—HTR6—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000692	0.0079	CbGpPWpGaD
Atomoxetine—HTR1D—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000686	0.00784	CbGpPWpGaD
Atomoxetine—NPY1R—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00068	0.00777	CbGpPWpGaD
Atomoxetine—HTR2A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000678	0.00775	CbGpPWpGaD
Atomoxetine—HTR1B—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000672	0.00768	CbGpPWpGaD
Atomoxetine—SLC6A2—brain—Gilles de la Tourette syndrome	0.00067	0.0132	CbGeAlD
Atomoxetine—NPY1R—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.000662	0.00757	CbGpPWpGaD
Atomoxetine—NPY1R—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00066	0.00754	CbGpPWpGaD
Atomoxetine—HTR2A—midbrain—Gilles de la Tourette syndrome	0.000641	0.0126	CbGeAlD
Atomoxetine—HTR2A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000631	0.00722	CbGpPWpGaD
Atomoxetine—NPY1R—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000615	0.00702	CbGpPWpGaD
Atomoxetine—HTR2C—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000606	0.00692	CbGpPWpGaD
Atomoxetine—Benzatropine—SLC6A3—Gilles de la Tourette syndrome	0.000599	0.0911	CrCbGaD
Atomoxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000582	0.00665	CbGpPWpGaD
Atomoxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000565	0.00646	CbGpPWpGaD
Atomoxetine—Maprotiline—SLC6A3—Gilles de la Tourette syndrome	0.000555	0.0844	CrCbGaD
Atomoxetine—HTR2A—nervous system—Gilles de la Tourette syndrome	0.000527	0.0104	CbGeAlD
Atomoxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000526	0.00602	CbGpPWpGaD
Atomoxetine—Pseudoephedrine—SLC6A3—Gilles de la Tourette syndrome	0.000516	0.0785	CrCbGaD
Atomoxetine—HTR2C—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000509	0.00582	CbGpPWpGaD
Atomoxetine—HTR2A—central nervous system—Gilles de la Tourette syndrome	0.000507	0.01	CbGeAlD
Atomoxetine—CYP3A4—nervous system—Gilles de la Tourette syndrome	0.000488	0.00962	CbGeAlD
Atomoxetine—CYP2D6—nervous system—Gilles de la Tourette syndrome	0.00048	0.00947	CbGeAlD
Atomoxetine—CYP3A4—central nervous system—Gilles de la Tourette syndrome	0.00047	0.00927	CbGeAlD
Atomoxetine—CYP2D6—central nervous system—Gilles de la Tourette syndrome	0.000462	0.00912	CbGeAlD
Atomoxetine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.000461	0.00527	CbGpPWpGaD
Atomoxetine—Modafinil—SLC6A3—Gilles de la Tourette syndrome	0.000444	0.0675	CrCbGaD
Atomoxetine—NPY1R—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000443	0.00507	CbGpPWpGaD
Atomoxetine—NPY1R—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00043	0.00492	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00043	0.00492	CbGpPWpGaD
Atomoxetine—Duloxetine—HTR2A—Gilles de la Tourette syndrome	0.000419	0.0637	CrCbGaD
Atomoxetine—Maprotiline—DRD2—Gilles de la Tourette syndrome	0.000413	0.0628	CrCbGaD
Atomoxetine—HTR2A—brain—Gilles de la Tourette syndrome	0.000403	0.00795	CbGeAlD
Atomoxetine—NPY1R—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000401	0.00458	CbGpPWpGaD
Atomoxetine—SLC6A4—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.000386	0.00442	CbGpPWpGaD
Atomoxetine—Benzphetamine—SLC6A3—Gilles de la Tourette syndrome	0.000385	0.0585	CrCbGaD
Atomoxetine—HTR2A—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.000369	0.00422	CbGpPWpGaD
Atomoxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000369	0.00421	CbGpPWpGaD
Atomoxetine—CYP2D6—brain—Gilles de la Tourette syndrome	0.000367	0.00724	CbGeAlD
Atomoxetine—HTR2A—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.000358	0.00409	CbGpPWpGaD
Atomoxetine—Fluoxetine—HTR2A—Gilles de la Tourette syndrome	0.000341	0.0519	CrCbGaD
Atomoxetine—SLC6A2—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.000332	0.0038	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.000325	0.00372	CbGpPWpGaD
Atomoxetine—Maprotiline—HTR2A—Gilles de la Tourette syndrome	0.000319	0.0485	CrCbGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.000316	0.00361	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.000294	0.00336	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000281	0.00321	CbGpPWpGaD
Atomoxetine—Desipramine—SLC6A3—Gilles de la Tourette syndrome	0.000274	0.0417	CrCbGaD
Atomoxetine—HTR1D—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.000268	0.00306	CbGpPWpGaD
Atomoxetine—HTR1B—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.000262	0.003	CbGpPWpGaD
Atomoxetine—HTR1D—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00026	0.00297	CbGpPWpGaD
Atomoxetine—HTR1B—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.000255	0.00291	CbGpPWpGaD
Atomoxetine—SLC6A4—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.000252	0.00288	CbGpPWpGaD
Atomoxetine—HTR6—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000251	0.00286	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000251	0.00286	CbGpPWpGaD
Atomoxetine—HTR1D—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000249	0.00284	CbGpPWpGaD
Atomoxetine—Nortriptyline—DRD2—Gilles de la Tourette syndrome	0.000248	0.0377	CrCbGaD
Atomoxetine—HTR1B—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000244	0.00278	CbGpPWpGaD
Atomoxetine—HTR6—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000243	0.00278	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000243	0.00278	CbGpPWpGaD
Atomoxetine—HTR1D—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.000242	0.00277	CbGpPWpGaD
Atomoxetine—HTR1D—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000241	0.00276	CbGpPWpGaD
Atomoxetine—HTR1B—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.000237	0.00271	CbGpPWpGaD
Atomoxetine—HTR1B—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000236	0.0027	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000228	0.0026	CbGpPWpGaD
Atomoxetine—HTR6—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000227	0.00259	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000227	0.00259	CbGpPWpGaD
Atomoxetine—HTR1D—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000225	0.00257	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000221	0.00252	CbGpPWpGaD
Atomoxetine—HTR1B—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00022	0.00252	CbGpPWpGaD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000215	0.00245	CbGpPWpGaD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000213	0.00244	CbGpPWpGaD
Atomoxetine—SLC6A2—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.000209	0.00239	CbGpPWpGaD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000209	0.00238	CbGpPWpGaD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000208	0.00238	CbGpPWpGaD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000207	0.00236	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000206	0.00235	CbGpPWpGaD
Atomoxetine—Desipramine—DRD2—Gilles de la Tourette syndrome	0.000204	0.031	CrCbGaD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000203	0.00232	CbGpPWpGaD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000194	0.00222	CbGpPWpGaD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000193	0.0022	CbGpPWpGaD
Atomoxetine—Nortriptyline—HTR2A—Gilles de la Tourette syndrome	0.000192	0.0291	CrCbGaD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000189	0.00216	CbGpPWpGaD
Atomoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000185	0.00211	CbGpPWpGaD
Atomoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000179	0.00205	CbGpPWpGaD
Atomoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000167	0.00191	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000164	0.00187	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000162	0.00185	CbGpPWpGaD
Atomoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00016	0.00183	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000159	0.00182	CbGpPWpGaD
Atomoxetine—HTR6—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000159	0.00181	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000159	0.00181	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000159	0.00181	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000158	0.00181	CbGpPWpGaD
Atomoxetine—Desipramine—HTR2A—Gilles de la Tourette syndrome	0.000158	0.024	CrCbGaD
Atomoxetine—HTR1D—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000158	0.0018	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000158	0.0018	CbGpPWpGaD
Atomoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000156	0.00178	CbGpPWpGaD
Atomoxetine—HTR1B—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000154	0.00176	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000154	0.00176	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000154	0.00175	CbGpPWpGaD
Atomoxetine—HTR2C—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.000151	0.00173	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000148	0.00169	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000147	0.00168	CbGpPWpGaD
Atomoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000145	0.00166	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000144	0.00165	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000144	0.00164	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000143	0.00163	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000137	0.00157	CbGpPWpGaD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000136	0.00155	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000135	0.00155	CbGpPWpGaD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000135	0.00154	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000134	0.00154	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000133	0.00152	CbGpPWpGaD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000132	0.00151	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00013	0.00149	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000124	0.00142	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000122	0.00139	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00012	0.00138	CbGpPWpGaD
Atomoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000117	0.00134	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000117	0.00134	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000109	0.00124	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000106	0.00122	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000105	0.0012	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000104	0.00118	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000103	0.00117	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000102	0.00116	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000101	0.00115	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.0001	0.00114	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	9.46e-05	0.00108	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	9.24e-05	0.00106	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	9.17e-05	0.00105	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	8.98e-05	0.00103	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	8.97e-05	0.00103	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	8.9e-05	0.00102	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	8.72e-05	0.000996	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	8.51e-05	0.000973	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	8.39e-05	0.000959	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	8.36e-05	0.000955	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	8.33e-05	0.000952	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	8.29e-05	0.000948	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	8.16e-05	0.000932	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	8.15e-05	0.000931	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	8.12e-05	0.000928	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	8.09e-05	0.000924	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	7.92e-05	0.000905	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	7.63e-05	0.000872	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	7.59e-05	0.000867	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	7.53e-05	0.000861	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	7.38e-05	0.000843	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	6.81e-05	0.000778	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	6.61e-05	0.000755	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—HDC—Gilles de la Tourette syndrome	6.46e-05	0.000739	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	6.18e-05	0.000706	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	6.15e-05	0.000703	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	6e-05	0.000686	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—HDC—Gilles de la Tourette syndrome	5.94e-05	0.000679	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	5.91e-05	0.000675	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	5.85e-05	0.000669	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	5.81e-05	0.000664	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	5.74e-05	0.000656	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	5.69e-05	0.00065	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	5.59e-05	0.000639	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	5.37e-05	0.000613	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	5.34e-05	0.000611	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	5.32e-05	0.000607	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	5.28e-05	0.000603	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	5.21e-05	0.000595	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	5.17e-05	0.00059	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	4.96e-05	0.000567	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	4.92e-05	0.000562	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	4.85e-05	0.000555	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	4.82e-05	0.000551	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	4.81e-05	0.00055	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	4.78e-05	0.000546	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	4.68e-05	0.000534	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	4.48e-05	0.000512	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	4.45e-05	0.000508	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	4.36e-05	0.000498	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	4.31e-05	0.000493	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	3.91e-05	0.000447	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—HDC—Gilles de la Tourette syndrome	3.89e-05	0.000444	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	3.65e-05	0.000417	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	3.54e-05	0.000405	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	3.3e-05	0.000377	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	3.17e-05	0.000362	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	3.14e-05	0.000359	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	3.12e-05	0.000356	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	3.08e-05	0.000352	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	3.05e-05	0.000349	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	2.87e-05	0.000328	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.31e-05	0.000264	CbGpPWpGaD
